

Biosparc Reaches Topping-Out Milestone as Cross-Border Life Sciences Partnerships Accelerate

November 20, 2025 — Suzhou

Biosparc, the China—Singapore Life Sciences Park, marked a key milestone today as its main structures reached topping-out in Suzhou Industrial Park. A strategic cooperation signing ceremony was held on the same day, with guests from Singapore and China in attendance.

A Solid Foundation for an International Innovation Accelerator

Launched at the end of 2023 and breaking ground in April 2024, Biosparc has now completed the structural phase of development. This infrastructure has been designed to support cross-border scientific research, clinical collaboration, and interdisciplinary innovation.

Strategic Partnerships: Building a China—Singapore Innovation Corridor

While the physical campus takes shape, Biosparc is also accelerating the buildout of its innovation ecosystem.

During the ceremony, Biosparc signed strategic agreements with the National Cancer Centre Singapore (NCCS), Essex Bio, Mirxes, and Suzhou Industrial Park Investment

Promotion and Operation Co. . These collaborations will span scientific research, clinical trials, early-stage industrialization, and translational development—deepening connectivity across research, clinical application, and regulatory pathways.

Biosparc also entered a tripartite strategic collaboration with True Light PE and ClavystBio. Together, the partners aim to support innovators from both China and Singapore in advancing research, clinical development, and early commercialization within the park. By leveraging each party's networks and capabilities, the partnership will strengthen cross-border R&D and establish a sustained pipeline for project landing and growth.

Toward a Globally Connected Life Sciences Ecosystem

With the simultaneous progress of infrastructure and strategic partnerships, Biosparc is shaping a platform capable of integrating resources from multiple countries and supporting cross-border innovation at scale.

Looking ahead, Biosparc will continue to anchor itself in Suzhou while using Singapore as a key bridge to global innovation. The park seeks to connect leading research institutes, clinical partners, multinational biopharma companies, and international investors—fostering a more integrated and globally connected life sciences ecosystem.